CHF3.15
4.55% today
SIX Swiss Exchange, Nov 07, 05:31 pm CET
ISIN
CH0363463438
Symbol
IDIA

Idorsia Stock price

CHF3.15
-1.53 32.69% 1M
+1.75 124.68% 6M
+2.33 283.21% YTD
+2.19 228.13% 1Y
-12.11 79.36% 3Y
-22.65 87.79% 5Y
-10.50 76.92% 10Y
-10.50 76.92% 20Y
SIX Swiss Exchange, Closing price Fri, Nov 07 2025
-0.15 4.55%
ISIN
CH0363463438
Symbol
IDIA
Industry

New AI Insights on Idorsia Insights AI Insights on Idorsia

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
CHF816.5m
Enterprise Value
CHF1.9b
Net debt
CHF1.1b
Cash
CHF83.3m
Shares outstanding
204.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.8 | 3.8
EV/Sales
8.9 | 8.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-239.6%
Return on Equity
21.8%
ROCE
-112.0%
ROIC
-49.4%
Debt/Equity
-1.1
Financials (TTM | estimate)
Revenue
CHF217.2m | CHF217.4m
EBITDA
CHF-139.7m | CHF-151.0m
EBIT
CHF-173.1m | CHF-124.7m
Net Income
CHF-133.3m | CHF-90.6m
Free Cash Flow
CHF-262.5m
Growth (TTM | estimate)
Revenue
69.9% | 93.2%
EBITDA
58.7% | 52.2%
EBIT
51.5% | 63.0%
Net Income
-565.1% | 65.7%
Free Cash Flow
37.7%
Margin (TTM | estimate)
Gross
82.8%
EBITDA
-64.3% | -69.4%
EBIT
-79.7%
Net
-61.4% | -41.7%
Free Cash Flow
-120.9%
More
EPS
CHF-0.7
FCF per Share
CHF-1.3
Short interest
-
Employees
650
Rev per Employee
CHF170.0k
Show more

Is Idorsia a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Idorsia Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Idorsia forecast:

1x Buy
8%
4x Hold
33%
7x Sell
58%

Analyst Opinions

12 Analysts have issued a Idorsia forecast:

Buy
8%
Hold
33%
Sell
58%

Financial data from Idorsia

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
217 217
70% 70%
100%
- Direct Costs 37 37
493% 493%
17%
180 180
48% 48%
83%
- Selling and Administrative Expenses 224 224
20% 20%
103%
- Research and Development Expense 107 107
42% 42%
49%
-140 -140
59% 59%
-64%
- Depreciation and Amortization 33 33
74% 74%
15%
EBIT (Operating Income) EBIT -173 -173
52% 52%
-80%
Net Profit -133 -133
565% 565%
-61%

In millions CHF.

Don't miss a Thing! We will send you all news about Idorsia directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus. The was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.

Head office Switzerland
CEO André Muller
Employees 650
Founded 2017
Website www.idorsia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today